Peanut (Ara h 2) IgE

If you or your child has had a worrying reaction to peanut, or you carry a vague peanut allergy label you have never confirmed, this is the blood test that can sharpen the picture. It zeroes in on the single peanut protein most responsible for serious reactions, and it does so with higher specificity than the standard peanut allergy blood test most people are first given. No blood test, including this one, replaces a supervised oral food challenge, which remains the gold standard for confirming or excluding peanut allergy.

A high result strongly suggests true peanut allergy in someone with a suggestive history. A very low or undetectable result makes clinically meaningful peanut allergy less likely, though roughly 1 in 7 truly allergic people can still be missed at standard cutoffs. That nuance matters because traditional testing often picks up harmless sensitization, leaving people on lifetime peanut avoidance they may not need, while no single blood test is sensitive enough to rule allergy in or out on its own.

What This Test Actually Measures

This test measures Ara h 2 IgE (immunoglobulin E antibodies against the peanut protein Ara h 2) in your blood. Ara h 2 is a 2S albumin seed storage protein and the dominant trigger of allergic reactions in most peanut-allergic people. IgE is the antibody class your immune system uses to drive allergic responses; when it binds to a specific food protein, it primes immune cells to release histamine and other chemicals on exposure.

In peanut allergy, IgE-producing cells are enriched in the stomach and lining of the small intestine, where the immune system first encounters food proteins. Many of these gut-based immune cells across different peanut-allergic patients make very similar antibodies against Ara h 2, which is part of why this single protein carries so much diagnostic weight.

How Ara h 2 Compares to the Standard Peanut Allergy Test

A standard peanut IgE test uses whole peanut extract, which contains many proteins. Some of those proteins, such as Ara h 8, cross-react with birch and other pollens and produce positive results in people who can eat peanut without any reaction. Ara h 2 targets the protein most closely tied to real, clinically significant reactions, which is why it is far more specific. The trade-off: Ara h 2 has somewhat lower sensitivity than whole-peanut IgE or skin prick testing, meaning it can miss a small fraction of people who truly have peanut allergy. In a 2020 meta-analysis, Ara h 2 picked up around 86% of true allergies, compared to roughly 95% for whole-peanut IgE and 97% for skin prick testing.

In high-risk infants who had never eaten peanut, an Ara h 2 blood test correctly flagged the large majority of truly allergic infants and correctly cleared most of those who could tolerate peanut, outperforming both whole-peanut blood testing and skin prick testing on overall accuracy. In UK children referred for suspected peanut allergy, Ara h 2 IgE correctly identified most allergic children and cleared most non-allergic ones when compared against a peanut food challenge. A pooled analysis of food allergy diagnostic tests found Ara h 2 had high specificity for peanut allergy, substantially higher than standard whole-peanut blood testing.

Sources: Keet et al. 2021; Hemmings et al. 2020; Riggioni et al. 2023; Greenhawt et al. 2020.

What this means for you: a normal-looking generic peanut IgE panel does not mean your Ara h 2 result is also fine, and a low Ara h 2 does not by itself rule out allergy in someone with a clear history. The 2020 AAAAI Practice Parameter currently does not recommend routine use of component testing as an add-on to skin prick testing or whole-peanut IgE, but Ara h 2 is the single component with the most useful diagnostic profile when component testing is used, and it is most informative when interpreted alongside your clinical history and other tests by an allergist.

Reaction Severity

Higher Ara h 2 IgE levels track on average with a higher likelihood of clinically meaningful, sometimes severe, reactions. In a double-blind, placebo-controlled food challenge study of children, Ara h 2 (along with the related protein Ara h 6) was the strongest blood predictor of moderate-to-severe peanut reactions. A study of 8-year-olds found children who experienced systemic symptoms after peanut exposure had higher Ara h 2 IgE levels than those with milder or no symptoms.

That said, Ara h 2 alone cannot reliably grade your risk. In the 2020 AAAAI analysis, an Ara h 2 level above 2 kUA/L had only modest accuracy for predicting severe reactions. People with low Ara h 2 sometimes still react severely, and people with moderately high levels sometimes have only mild reactions. Test results inform risk; they do not lock it in.

Outgrowing Peanut Allergy

Peanut allergy can resolve, and Ara h 2 IgE often tracks that change. In a long-term Australian cohort of 156 children, those whose Ara h 2 IgE fell over time, with a parallel rise in Ara h 2-specific IgG4 antibodies (a calming, blocking antibody), were the ones most likely to outgrow their allergy. About a third (33.9%) of infants in that cohort had resolved their peanut allergy by age 10, with most of that resolution (around 97%) occurring by age 6.

This is the strongest argument for tracking Ara h 2 over years rather than treating one number as a verdict. A falling trajectory is genuinely encouraging information, particularly during the early childhood window when most natural resolution occurs.

Monitoring Peanut Immunotherapy

If you or your child is on peanut oral immunotherapy (gradually introducing tiny, increasing doses of peanut under medical supervision), Ara h 2 IgE typically falls during treatment while IgG4 rises. In a randomized trial of children with severe peanut allergy, oral immunotherapy lowered IgE to Ara h 2 specifically. Higher and more durable rises in neutralizing IgG4 against Ara h 2 have been linked to lasting protection after stopping treatment. Tracking Ara h 2 alongside immunotherapy gives you objective evidence that the immune system is actually shifting, not just that you happen to be tolerating doses.

Why One Reading Is Not Enough

A single Ara h 2 number is a snapshot. The most useful information comes from how that number changes. Children sometimes drift from sensitization toward true allergy, or from allergy toward tolerance, over months and years. Adults who suspect their childhood peanut allergy may have faded need a trajectory, not a guess. People on immunotherapy need to see whether the underlying immune wiring is actually changing.

A reasonable cadence, drawn from clinical practice rather than a specific guideline recommendation: a baseline measurement, then retest every 6 to 12 months if you are watching for resolution, monitoring immunotherapy, or trying to clarify an ambiguous initial result. If your level is borderline, retest before making any decisions about reintroducing peanut. Decisions about actually eating peanut after a borderline or downtrending result should be made with an allergist, typically using a supervised oral food challenge.

When Results Can Be Misleading

Ara h 2 is highly specific, but no test is perfect. A few patterns are worth knowing:

• Low but positive results can confuse: levels between truly allergic and merely sensitized people overlap at the low end. A small positive does not automatically mean reaction on exposure, and it often requires an oral food challenge to interpret.
• False negatives are not rare: roughly 1 in 7 people with true peanut allergy can be missed by Ara h 2 alone at standard cutoffs. If your history strongly suggests reaction, a negative Ara h 2 should not close the case, and additional testing such as whole-peanut IgE, skin prick testing, a basophil activation test, or a supervised challenge may be needed.
• Population matters: the result interpretation varies by country and age group, so your result is most meaningful when read alongside your clinical history.
• Other peanut proteins matter occasionally: in a minority of cases, the dominant trigger is a related protein called Ara h 6 rather than Ara h 2. Most of the time these two move together, but if Ara h 2 is unexpectedly negative in someone with a clear reaction history, testing Ara h 6 can fill the gap.

Decision Pathway for Out-of-Pattern Results

A clearly elevated Ara h 2 in someone with a history of reaction strongly supports peanut allergy and shifts the conversation to avoidance, emergency epinephrine, and whether to consider oral immunotherapy. No single blood test is fully confirmatory on its own; an oral food challenge remains the definitive standard. A clearly elevated Ara h 2 in someone who has never knowingly eaten peanut, especially a high-risk infant, calls for evaluation by an allergist before any peanut introduction at home.

A low or undetectable Ara h 2 in someone carrying a peanut allergy label they have never confirmed is the most actionable finding, particularly when paired with a negative skin prick test or whole-peanut IgE. It opens the door to a supervised oral food challenge with an allergist, which is the only definitive way to confirm that peanut is safe to reintroduce. Do not act on a low Ara h 2 by eating peanut at home. The combination of Ara h 2 with a skin prick test or whole-peanut IgE, and sometimes a basophil activation test, is what allergists use to decide whether a challenge is appropriate.